How to buy OrCam shares when it goes public

OrCam Technologies, an Israeli company that develops devices to aid the visually impaired, is expected to conduct an initial public offering. The deal will reportedly be led by Goldman Sachs & Co. We will update this story as new information emerges.

How to buy shares in OrCam when it goes public

Once OrCam goes public, you'll need a brokerage account to invest. Consider opening a brokerage account today so you're ready as soon as the stock hits the market.

1. Compare share trading platforms. Find a platform that suits your investing style. In this case, you might need a brokerage providing access to newly listed stocks. Narrow down top brands with our comparison table.
2. Open and fund your brokerage account. Create an account using basic personal details along with your ID and bank information. You can make a deposit with a bank transfer, credit card or debit card.
3. Search for OrCam. Find the stock by name or the ticker symbol .
4. Buy OrCam shares. Once shares become available on your platform, decide how much stock you want to buy and create an order.

Our top picks for where to buy shares

Best for 0% commission stocks

Finder Award

Go to site

Capital at risk. T&Cs apply.

Copy picks from top traders

Commission-free trades
Fractional shares
Get dividend payments

Best for fractional shares

Go to site

Capital at risk. T&Cs apply.

Earn 4.75% on uninvested funds

Commission-free trades
Fractional shares
5,400+ stocks/ETFs

Best for customer satisfaction

Finder Award

Go to site

Capital at risk. T&Cs apply.

97% would recommend

Free fund trading
Expert insights
Wide range of accounts

What we know about the OrCam IPO

OrCam Technologies is expected to go public during 2021. The company is hoping to raise $300 million in the IPO, based upon a $3 billion valuation.

OrCam is reportedly planning to conduct a pre-IPO funding round to raise $150 million to $200 million.

How do similar companies perform?

It's impossible to predict how any stock will perform — and IPOs can be particularly volatile. But evaluating the performance of companies like OrCam can be useful in determining how the market is performing and whether now is a good time to invest in this industry. Select a company to learn more about what it does and how its stock performs, including market capitalisation, the price-to-earnings (P/E) ratio, price/earnings-to-growth (PEG) ratio and dividend yield. While this list includes a selection of the most well-known and popular stocks, it doesn't include every stock available.

• Nuance Communications (NUAN.US)

  Company summary

  Nuance Communications, Inc. provides conversational and cognitive artificial intelligence (AI) innovations that bring intelligence to everyday work and life. The company delivers solutions that understand, analyze, and respond to people - amplifying human intelligence to increase productivity and security. Its Healthcare segment provides clinical speech and clinical language understanding solutions that improve the clinical documentation process, from capturing the complete patient record to improving clinical documentation and quality measures for reimbursement. Its solutions include Dragon Medical One, cloud-based speech solution; computer-assisted physician documentation; diagnostic imaging solutions; Nuance Dragon Ambient eXperience, a voice-enabled solution; and clinical documentation improvement and coding. The company's Enterprise segment primarily engages in using speech, natural language understanding, and artificial intelligence to provide automated customer solutions and services for voice, mobile, web, and messaging channels. Its solutions include intelligent engagement solutions; Conversational AI; Engagement AI; and Security AI. Its Other segment provides voicemail transcription services. It serves organizations across healthcare, financial services, telecommunications, government, and retail. The company markets and sells its solutions and technologies directly through sales force, as well as through a network of resellers, including system integrators, independent software vendors, value-added resellers, distributors, hardware vendors, telecommunications carriers, and e-commerce Websites worldwide. The company was formerly known as ScanSoft, Inc. and changed its name to Nuance Communications, Inc. in October 2005. Nuance Communications, Inc. was incorporated in 1992 and is headquartered in Burlington, Massachusetts. As of March 4, 2022, Nuance Communications, Inc. operates as a subsidiary of Microsoft Corporation.

  Historical performance

  Stock information

  • Market capitalization: $17882421248
  • PEG ratio: 13.72
  • Dividend yield: 0%

  Get more detailed information and learn how to buy NUAN.US shares

• Medtronic (MDT.US)

  Company summary

  Medtronic plc develops, manufactures, and sells device-based medical therapies to healthcare systems, physicians, clinicians, and patients worldwide. The Cardiovascular Portfolio segment offers implantable cardiac pacemakers, cardioverter defibrillators, and cardiac resynchronization therapy devices; cardiac ablation products; insertable cardiac monitor systems; TYRX products; and remote monitoring and patient-centered software. It also provides aortic valves, surgical valve replacement and repair products, endovascular stent grafts and accessories, and transcatheter pulmonary valves; and percutaneous coronary intervention products, percutaneous angioplasty balloons, and other products. The Neuroscience Portfolio segment offers medical devices and implants, biologic solutions, spinal cord stimulation and brain modulation systems, implantable drug infusion systems, and interventional products, as well as nerve ablation system under the Accurian name. The segment offers its products for spinal surgeons, neurosurgeons, neurologists, pain management specialists, anesthesiologists, orthopedic surgeons, urologists, urogynecologists, and interventional radiologists, as well as ear, nose, and throat specialists; and energy surgical instruments. The Medical Surgical Portfolio segment offers surgical stapling devices, vessel sealing instruments, wound closure and electrosurgery products, AI-powered surgical video and analytics platform, robotic-assisted surgery products, hernia mechanical devices, mesh implants, gynecology products, gastrointestinal and hepatologic diagnostics and therapies, and therapies to treat other non-exclusive diseases and conditions; and patient monitoring and airway management products. The Diabetes Operating Unit segment provides insulin pumps and consumables, continuous glucose monitoring systems, and InPen, a smart insulin pen system. The company was founded in 1949 and is headquartered in Galway, Ireland.

  Historical performance

  Stock information

  • Market capitalization: $102621667328
  • P/E ratio: 24.474
  • PEG ratio: 1.4856
  • Dividend yield: 0.032%

  Get more detailed information and learn how to buy MDT.US shares

• Abbott Laboratories (ABT.US)

  Company summary

  Abbott Laboratories, together with its subsidiaries, discovers, develops, manufactures, and sells health care products worldwide. It operates in four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The company provides generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm, intrahepatic cholestasis or depressive symptoms, gynecological disorder, hormone replacement therapy, dyslipidemia, hypertension, hypothyroidism, Ménière's disease and vestibular vertigo, pain, fever, inflammation, and migraine, as well as provides anti-infective clarithromycin, influenza vaccine, and products to regulate physiological rhythm of the colon. It also offers laboratory and transfusion medicine systems in the areas of immunoassay, clinical chemistry, hematology, and transfusion; molecular diagnostics polymerase chain reaction instrument systems that automate the extraction, purification, and preparation of DNA and RNA from patient samples, and detect and measure infectious agents; point of care systems; cartridges for testing blood gas, chemistry, electrolytes, coagulation, and immunoassay; rapid diagnostics lateral flow testing products; molecular point-of-care testing for HIV, SARS-CoV-2, influenza A and B, RSV, and strep A; cardiometabolic test systems; drug and alcohol test, and remote patient monitoring and consumer self-test systems; and informatics and automation solutions for laboratories. In addition, the company provides pediatric and adult nutritional products; rhythm management, electrophysiology, heart failure, vascular, and structural heart devices for the treatment of cardiovascular diseases; diabetes care products, such as glucose and blood glucose monitoring systems; and neuromodulation devices for the management of chronic pain and movement disorders. Abbott Laboratories was founded in 1888 and is based in North Chicago, Illinois.

  Historical performance

  Stock information

  • Market capitalization: $194138112000
  • P/E ratio: 34.0213
  • PEG ratio: 2.1998
  • Dividend yield: 0.0211%

  Get more detailed information and learn how to buy ABT.US shares

Share dealing platform comparison

1 - 5 of 7

Updated regularly

Product UKFST	Finder Score	Min. initial deposit	Price per trade	Frequent trader rate	Platform fees	Offer	Link
eToro Finder AwardFree Trades	9Excellent	$100	£0 on stocks	N/A	£0		Go to site Capital at risk Platform details Compare	loading Fetching your data...
Freetrade Free TradesOffer	9.1Excellent	£1	£0	N/A	£0	Get a free share worth up to £100 when you sign up and deposit at least £50. T&Cs apply. Capital at risk.	Go to site Capital at risk Platform details Compare	loading Fetching your data...
Trading212 Free TradesOffer	10Excellent	£1	£0	£0	£0	Get free fractional shares worth up to £100 when you sign up with Finder’s link and use the code “FINDER”. T&Cs apply. Capital at risk.	Go to site Capital at risk Platform details Compare	loading Fetching your data...
XTB Free Trades	9Excellent	£0	£0	£0	£0	Earn up to 4.75% interest on uninvested cash.	Go to site Capital at risk Platform details Compare	loading Fetching your data...
CMC Invest Finder Award	9Excellent	£0	£0	N/A	£0	Get your first 3 months free when you upgrade to Plus plan. T&Cs apply. Capital at risk.	Go to site Capital at risk Platform details Compare	loading Fetching your data...

loading

Prev

1 2

Next

Finder Score for trading platforms

To make comparing even easier we came up with the Finder Score. Costs, features, ease and range of investments across 30+ platforms are all weighted and scaled to produce a score out of 10. The higher the score the better the platform – simple.